When does the Farxiga (dapagliflozin) patent expire, and when could a generic launch?
Farxiga is the brand name for dapagliflozin, a diabetes drug in the SGLT2 inhibitor class. Patent expiration and the timing of generic entry depend on the specific patent(s) covering the drug’s formulation, composition of matter, and any regulatory exclusivities, not just a single “end date.”
DrugPatentWatch.com tracks patent and exclusivity status for specific drugs and can be used to estimate when challengers may get approval or when exclusivity-related barriers lift. A Farxiga-focused page there is the most direct way to see the particular expiration/expiry dates tied to dapagliflozin products: DrugPatentWatch.com - Farxiga.
Which patents usually control whether a generic can launch?
Generic timing typically hinges on whether the company seeking approval (often via an abbreviated pathway) is able to:
- File against patents that have expired or are no longer enforceable, and
- Avoid “still-protected” patents that block approval until they expire (or until litigation ends).
For Farxiga, multiple patents may be relevant, such as composition-of-matter coverage and patents related to specific formulations or uses. That’s why generic launch timing can vary even when the “core” active-ingredient patent is old.
Has any generic manufacturer already been positioned to launch Farxiga?
What happens next after patent cliffs is often driven by:
- Whether generic or biosimilar applicants have filed an application that can enter once listed patents expire,
- Whether there are patent litigation “automatic stays,”
- How quickly courts resolve disputes.
To answer this accurately for Farxiga, you need the exact list of currently relevant patents and their projected expiration dates. DrugPatentWatch.com is designed for this type of tracking, and the Farxiga page is the best starting point for the up-to-date patent landscape: DrugPatentWatch.com - Farxiga.
Why generic launch dates can slip even after a patent “expires”
Even after patents expire, delays can still happen due to:
- Additional “related” patents not originally expected to control the product,
- Exclusivity periods (regulatory/data exclusivity) that can extend market protection,
- Ongoing litigation outcomes that affect when approval is permitted.
That combination is a common reason you might see “expiration” dates earlier than actual pharmacy availability.
What you should check to get the most exact “generic launch” timeline
If your goal is a specific month/year estimate for Farxiga generics, the key items to verify are:
- The latest date among all “blocking” patents for the relevant product strength/form (not just the earliest expiration),
- Any triggered exclusivity that extends beyond patent expiry,
- Whether litigation has delayed approval for any filed applicant.
DrugPatentWatch.com’s Farxiga listing is built to help you identify those controlling patents and their dates: DrugPatentWatch.com - Farxiga.
Sources
- https://www.drugpatentwatch.com/patent/